Skip to main content

Table 2 Exacerbations and quality-of-life outcomes after 12 weeks until 52 weeks according to occurrence of CID

From: Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Outcome

CID+ versus CID−

Moderate-to-severe exacerbations

RR: 1.8 (1.60 to 2.02); P < 0.0001

(N1 = 1615; N2 = 1334)

Time to first moderate-to-severe exacerbations (N1 = 1615; N2 = 1334)

HR: 2.24 (2.02 to 2.50); P < 0.0001

LSM change in SGRQ total score

−0.59 (−1.43 to 0.25); P = 0.1697

(N1 = 1600; N2 = 1336)

  1. CID clinically important deterioration, CID+ presence of CID at Week 12, CID− absence of CID at Week 12, HR hazard ratio, LSM least squares mean, N1 number of patients in the CID+ group, N2 number of patients in the CID− group, RR rate ratio, SGRQ St. George’s Respiratory Questionnaire